City

Beijing (1)

Condition

EGFR Gene Mutation (2)

Non Small Cell Lung Cancer Stage IIIA (2)

Non Small Cell Lung Cancer (1)

Non Small Cell Lung Cancer Stage IIIB (1)

Non-small Cell Lung Cancer Stage IV (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 2 (1)

Sponsor

Betta Pharmaceuticals Co., Ltd. (1)

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1)

Collaborator

Intervention

furmonertinib (1)

icotinib (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (1)

Observational (1)

non small cell lung cancer stage iiia

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Double-dose Furmonertinib in Treatment of Slow

Not yet recruiting

Non Small Cell Lung Cancer
+3 more

Furmonertinib

(no location specified)

Oct 31, 2023

EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA, Non Small Cell Lung Cancer Stage IIIB Trial in Beijing (Icotinib)

Recruiting

EGFR Gene Mutation
+2 more

Icotinib

Beijing, China

Cancer Hospital, Chinese Academy of Medical Science

Jul 17, 2018